ProKidney Corp. (PROK)
NASDAQ: PROK · Real-Time Price · USD
3.130
+0.140 (4.68%)
Oct 14, 2025, 1:18 PM EDT - Market open
ProKidney Revenue
ProKidney had revenue of $221.00K in the quarter ending June 30, 2025. This brings the company's revenue in the last twelve months to $527.00K. In the year 2024, ProKidney had annual revenue of $76.00K.
Revenue (ttm)
$527.00K
Revenue Growth
n/a
P/S Ratio
1,675.23
Revenue / Employee
$2,583
Employees
204
Market Cap
921.10M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 76.00K | - | - |
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
PROK News
- 25 days ago - ProKidney: Slow-Burning 'Buy' Opportunity Based On 2027 Approval Of Kidney Disease Therapy - Seeking Alpha
- 5 weeks ago - ProKidney Corp. (PROK) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 5 weeks ago - ProKidney Corp. (PROK) Presents At Citi's Biopharma Back To School Conference Transcript - Seeking Alpha
- 6 weeks ago - ProKidney to Participate in Two Upcoming Conferences: the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare Conference - GlobeNewsWire
- 2 months ago - ProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates - GlobeNewsWire
- 3 months ago - ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel - GlobeNewsWire
- 3 months ago - ProKidney: What's Happening With PROK Stock? - Forbes
- 3 months ago - ProKidney to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference - GlobeNewsWire